
We are turning 10!
Join us for a reception on November 30 at the Grand Concourse to see how far we’ve come with your support … and just how far we plan to go.

- There are no upcoming events.
- There are no upcoming events.
Latest Past Events
Rare Liver Disease Program
December 6, 2023 7:00-9:00 p.m. EST Register Now! Program Sponsors: *Industry partners must have an exhibit or sponsorship to participate in the Community Liver Alliance programs and events. Your support allows the […]
Post-AASLD
December 5, 2023 6:00-9:00 p.m. EST Virtual CME Program The Community Liver Alliance is planning its 10th Annual Post-AASLD Program led by Course Directors Michael Babich, MD with Allegheny Health […]
10th Anniversary Celebration
Grand Concourse 100 W Station Square Drive, PittsburghNovember 30, 2023 6:00-8:00 p.m. Grand Concourse (Station Square, Pittsburgh) $50 per person Click here to register! The Community […]
Advocacy

Medicare Cuts Worrisome
Letter to the Editor: Medicare Cuts Worrisome Trib Live September 2021 As I work with Medicare seniors in Pennsylvania, I am concerned about prospective cuts to clinical lab services. In

Suzanna Masartis Speaks Out for Hep C
Testimony of Suzanna Masartis Executive Director, Community Liver Alliance Joint Informational Meeting of the Pennsylvania House Health and Insurance Committees Monday, April 20, 2015 My name is Suzanna Masartis and
Advocacy
There is 80 to 100 million people in the USA that have Fatty Liver Disease and most do not even know they have it. Liver Disease does not discriminate. It affects any age, social economics and race. Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time.
Ensure funding for COVID-19 and liver disease public health programs, research, vaccine dissemination; ensure that people living with liver disease are not disproportionately impacted and do not experience unnecessary or discriminatory health care or treatment disruptions.
Address inequities in the care of people impacted by liver disease, especially the excess incidence rate of liver cancer in black men in America.
Advance the U.S. NASH Action Plan, and ensure patients with liver disease perspectives are represented in relevant legislative packages: COVID-19, diabetes, and obesity.
Work with regulators to establish logical pathways to consistently approve therapies for liver diseases, particularly rare liver diseases.
Advocate for funding that ensures meaningful growth of vital liver disease research and the improving of liver health.
Urgently respond to the inequities that impact organ transplantation; modernize the U.S. Organ Donation system, improve care for transplant patients, and increase the number of available organs.
Increase support for hepatitis programs and raise awareness of viral hepatitis; advocate for the elimination of viral hepatitis .
Advance health care policies that reflect each person’s unique needs and drive access to personalized, patient-centric care.
Support policy solutions that curb patients’ health care expenses; advocate for the smoothing and capping of out-of-pocket costs in Medicare Part D.







